UNH

Unitedhealth Group
D

UNH

Arincen63/100B
409.28
USD
5.31
(1.31%)
Post Trading·411.20USD+1.92(+0.47%)
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 2.28Revenue estimate 112.26B
OverviewFinancialsSignalsNewsForecastEarningsDividendsCompany

Unitedhealth Group executives and insider trading

Patrick Hugh Conway sold 2,469 shares for 944,910 USD in 3 sales over the last twelve months, the last on 21 August 2026, and bought none on the open market.

Over the last twelve months Unitedhealth Group's insiders sold 2,469 shares for 944,910 USD in 3 sales on the open market, and bought 0 shares in 0 purchases.

Insiders over the last twelve months

Insider sales
3
Shares sold
2,469
Value sold
944.91K USD
Insider purchases
0

Insiders buying against selling

Bought on the market
Sold on the market
0
1 week
0
0
1 month
0
0
3 months
455.91K USD
0
6 months
660.91K USD
0
1 year
944.91K USD
32.12M USD
2 years
1.57M USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
Patrick Hugh Conway CEOChief Executive Officer of Optum512,469944.91K USD—21 Aug 202615,419

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
21 Aug 2026Patrick Hugh ConwaySale1,169390.00455.91K USD15,328Form 4
5 Aug 2026Patrick Hugh ConwaySale500410.00205.00K USD16,497Form 4
23 Apr 2026Patrick Hugh ConwaySale800355.00284.00K USD17,805Form 4
11 Sept 2025Charles D. BakerSale27356.059.61K USD—Form 4
10 Jun 2025Patrick Hugh ConwaySale589305.00179.65K USD10,398Form 4
16 May 2025John F RexPurchase17,175291.125.00M USD203,796Form 4
16 May 2025Stephen J. HemsleyPurchase86,700288.5725.02M USD679,493Form 4
15 May 2025Kristen GilPurchase3,700271.171.00M USD3,818Form 4
14 May 2025Timothy Patrick FlynnPurchase1,533320.80491.79K USD6,033Form 4
14 May 2025John H NoseworthyPurchase300312.1693.65K USD6,063Form 4
17 Jan 2025Timothy Patrick FlynnPurchase1,000511.58511.58K USD4,500Form 4
11 Nov 2024Erin L. McSweeneySale701626.23438.99K USD7,105Form 4

Common questions about Unitedhealth Group's executives and insiders

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.